As of Nov 21
| -0.12 / -2.44%|
The 8 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 7.00, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +45.83% increase from the last price of 4.80.
The current consensus among 9 polled investment analysts is to Hold stock in Keryx Biopharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.